Xhale submits Biomarker Qualification package to FDA for Medication Adherence Monitoring Tool. Gainesville, FL, September 21, 2015 Xhale, Inc. announced today that it has submitted to the Food and Drug Administration (FDA) the first Biomarker Qualification package for a Drug Development Tool for medication adherence monitoring. The submittal to FDA marks an important step […]
Xhale Assurance announced today that it has received CE Mark approval for its Nasal Alar SpO2 Sensor which allows for nasal ala oximetry utilizing a highly dependable central site. GAINESVILLE, FL August 21, 2015 – Xhale Assurance, Inc. Xhale Assurance, Inc. today announced it has received CE Mark approval of its Nasal Alar […]
Douglas M. Crumb Appointed President of Xhale, Inc. GAINESVILLE, FL June 2, 2015 Xhale, Inc., a medical technology company developing and commercializing unique monitoring solutions for the pharmaceutical and healthcare industries, announced the appointment of Douglas M. Crumb to the role of President and Chief Operating Officer of the company. In this position, Mr. Crumb […]
Xhale Assurance, Inc., developer of the patented Assurance® Nasal AlarSpO2TM Sensor, today announced FDA clearance and the global launch of its second-generation pulse oximetry sensor. The new Assurance® Nasal AlarSpO2TM Sensor is now compatible with the majority of pulse oximetry monitors in use in a wide variety of health care settings. “The Assurance® Nasal AlarSpO2TM […]
